Table 3.

Response by Baseline BCR-ABL Mutation

Mutation Status	Total	Patients With Major HR	Patients With MCyR
No mutation
No. of patients	68	38	27
Total patients	156	68	68
%	44	56	40
Any mutation
No. of patients	88	64	35
Total patients	156	88	88
%	56	73	40
Mutations associated with an increased IM IC50 of at least 5-fold
No. of patients	58	39	20
Total patients	156	58	58
%	37	67	34
Specific BCR-ABL point mutations, n*†
L248V (NR)	3	3	2
E355G (NR)	4	2	2
V379I (IC50 IM: 1,630 nmol/L; DA: 0.8 nmol/L)†	6	4	4
S417Y (NR)	3	1	0
E459K (NR)	3	1	3
M351T (IC50 IM: 880 nmol/L; DA: 1.1 nmol/L)†	11	9	3
F317L (IC50 IM: 1,050 nmol/L; DA: 7.4 nmol/L)†	4	4	0
G250E (IC50 IM: 1,350 nmol/L; DA: 1.8 nmol/L)†	10	6	2
H396R (IC50 IM: 1,750 nmol/L; DA: 1.3 nmol/L)†	6	4	2
F359V (IC50 IM: 1,825 nmol/L; DA: 2.2 nmol/L)†	8	6	2
M244V (IC50 IM: 2,000 nmol/L; DA: 1.3 nmol/L)†	6	5	4
E255K (IC50 IM: 5,200 nmol/L; DA: 5.6 nmol/L)†	8	5	1
Y253H (IC50 IM: > 6,400 nmol/L; DA: 1.3 nmol/L)†	9	8	4
T315I (IC50 IM: > 6,400 nmol/L; DA: > 200 nmol/L)†	9	0	0

Abbreviations: HR, hematologic response; MCyR, major cytogenetic response; IM, imatinib; IC₅₀, half maximal inhibitory concentration; NR, not reported by O'Hare et al¹⁵; DA, dasatinib.

^*Reported in three or more patients.

^†Cellular imatinib and dasatinib IC₅₀ values taken from O'Hare et al.¹⁵